Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H22N2O4S |
Molecular Weight | 278.368 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCS
InChI
InChIKey=ZNXZGRMVNNHPCA-VIFPVBQESA-N
InChI=1S/C11H22N2O4S/c1-11(2,7-14)9(16)10(17)13-4-3-8(15)12-5-6-18/h9,14,16,18H,3-7H2,1-2H3,(H,12,15)(H,13,17)/t9-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19685700Curator's Comment: The description was created based on several sources, including
https://goo.gl/fGS8b3 | http://ecmdb.ca/compounds/M2MDB000501 | https://www.ncbi.nlm.nih.gov/pubmed/20018163 | https://www.ncbi.nlm.nih.gov/pubmed/3734807 | http://www.anaturalhealingcenter.com/documents/Thorne/articles/Pantethine.pdf | https://www.ncbi.nlm.nih.gov/pubmed/28576495
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19685700
Curator's Comment: The description was created based on several sources, including
https://goo.gl/fGS8b3 | http://ecmdb.ca/compounds/M2MDB000501 | https://www.ncbi.nlm.nih.gov/pubmed/20018163 | https://www.ncbi.nlm.nih.gov/pubmed/3734807 | http://www.anaturalhealingcenter.com/documents/Thorne/articles/Pantethine.pdf | https://www.ncbi.nlm.nih.gov/pubmed/28576495
Pantetheine is the mercaptoethyl conjugated amide analog of pantothenic acid (Vitamin B5), an intermediate in the production of coenzyme A by the body. Pantetheine is part of two larger compounds (coenzyme A and acyl-carrier protein) that promote a large number of metabolic reactions essential for the growth and well-being of animals. Pantetheine has been found to ameliorate symptoms in various disease models but specifically in Pantothenate Kinase-Associated Neurodegeneration (PKAN). Pantetheine is usually administered in its disulfide form (i.e. pantethine) since pantethine is commercially available and is reduced to pantetheine in biological systems and pantethine was hydrolyzed to pantetheine and pantothenic acid prior to absorption. The applicability and efficacy of pantethine (therefore also pantetheine) as a clinical therapeutic however is hampered since both forms can be degraded by pantetheine present in the body.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL613740 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28576495 |
|||
Target ID: WP462 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7854449 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Pantesin® Pantethine Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26350816
600 mg/day was administered for 8 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28576495
A549 cells were seeded (2 x 10^5 cells/well) in 24-well plates and cultured with MEM supplemented with 10% FBS at 37 C under 5% CO2. For the pretreatment of the compounds, the confluent monolayers were washed once with FBS-free MEM at 24 h prior to virus inoculation, and incubated in FBS-free MEM supplemented with the pantetheine (0, 0.4 or 2 mM). For virus inoculation, A549 cells are infected with IAV at a multiplicity of infection (MOI) of 0.1 PFU/cell or mock-infected. One hr later, the virus inocula were removed, and infected cells were washed twice and then maintained in FBS-free MEM supplemented with trypsin (1.0 mkg/ml) and the pantetheine (0, 0.4 or 2 mM) at 34 C under 5% CO2. At designated hr post-inoculation (h.p.i.), culture supernatants were harvested for the plaque assay, and A549 cells were directly lysed with lysis buffer for RNA extraction and subjected to the measurement of viral and cellular mRNA. Five hundred mkl of IAV(1 x 10^5 PFU/100 ml) and an equal amount MEM containing 0, 0.4 or 2 mM of test substances (pantetheine, cysteamine, or pantothenic acid) were mixed and incubated for 30 min at 34 C, and then 100 mkl of the mixtures was subjected to the plaque assay.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
496-65-1
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY | |||
|
207-824-1
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY | |||
|
DTXSID50862039
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY | |||
|
439322
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY | |||
|
m8384
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
16753
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY | |||
|
VCH6X4IARE
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY | |||
|
Pantetheine
Created by
admin on Sat Dec 16 09:04:24 GMT 2023 , Edited by admin on Sat Dec 16 09:04:24 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD